###### Strengths and limitations of this study

-   This review included large sample size to reveal the relationship between the expression of liver kinase B1 (LKB1) and solid tumours.

-   Subgroup analyses and sensitivity analyses were performed to confirm the findings.

-   The cut-off value of LKB1 among the included studies were inconsistent.

Introduction {#s1}
============

The serine/threonine kinase liver kinase B1 (LKB1), also known as STK11, was originally observed to be mutated in the genes of patients with Peutz-Jeghers syndrome.[@R1] LKB1 is often mutated in lung, breast, gastric and other cancers.[@R2] LKB1 plays key roles in multiple cellular processes, including cell structure control, cell cycle regulation, apoptosis and cellular metabolism.[@R5] LKB1 phosphorylates multiple substrates, including AMPK, to act as a tumour suppressor to restrict tumourigenesis and metastasis.[@R8] Mice with a regulatory T cell (Treg)-specific deletion of LKB1 develop a fatal inflammatory disease, and LKB1 in Treg cells acts not through signalling by AMPK or the mammalian target of rapamycin complex 1 (mTORC1) and hypoxia-inducible factor 1, but through signalling involving programmed cell death protein 1 and TNF receptor proteins.[@R9] LKB1 deficiency can render tumour cells sensitive to metabolic stress, which may turn out to be an antitumour strategy.[@R10]

Although several studies have examined the role of LKB1 in tumour inhibition, its role in the prognosis of solid tumours has not been conclusively determined. Several studies suggest that decreased LKB1 expression indicates poor prognosis. In fact, meta-analysis showed that decreased LKB1 expression in patients with solid tumours may be related to poor prognosis and serve as a predictor of clinicopathological prognostic factors.[@R11] However, other studies have not reproduced these findings, and some have even suggested that decreased LKB1 may correlate with favourable survival.

Therefore, we systematically reviewed and meta-analysed the relevant literature to understand the current evidence about a relationship between LKB1 expression and prognosis in patients with solid tumours.

Materials and methods {#s2}
=====================

Literature search strategy {#s2a}
--------------------------

The following databases were searched from database establishment to 15 June 2018 to identify studies of LKB1 expression and survival in solid tumours: PubMed, Embase, Web of Science, Cochrane Database, the Chinese National Knowledge Infrastructure and Wang Fang. Searches were carried out using terms such as LKB1, STK11, liver kinase B1, prognosis, prognostic, survival and overall survival. For example, we searched PubMed using the following strategy: (LKB1(tw) OR STK11(tw) OR 'liver kinase B1'(tw) OR 'serine-threonine kinase 11'(tw)) AND ('prognosis' (MeSH terms) OR prognoses(tw) OR prognostic(tw) OR 'prognostic factor'(tw) OR 'prognostic factors'(tw) OR factor(tw) OR factors(tw) OR outcome(tw) OR survival(tw) OR metastases(tw) OR metastasis(tw) OR migration(tw) OR transplantation(tw) OR transfer(tw) OR shift(tw) OR divert(tw) OR recurrence(tw) OR relapse(tw) OR reappear(tw) OR recur(tw) OR recidivation(tw) OR invasion(tw)).

Study inclusion and exclusion criteria {#s2b}
--------------------------------------

Studies were considered eligible if they met the following criteria: (1) LKB1 expression in cancer tissue (obtained via surgery or biopsy) was measured by immunohistochemistry or western blot analysis; (2) the association was studied between LKB1 expression and clinicopathological characteristics, overall survival (OS), disease-free survival (DFS) or recurrence-free survival (RFS) of patients with solid tumours; (3) sufficient data were published for calculating an OR or HR and 95% CI and (4) the study was published as a full-text article in English or Chinese. If we retrieved multiple studies conducted by the same research group and involving overlapping patient populations, only the most recent or most complete study was included in the meta-analysis. Articles were excluded if they (1) were duplicate publications; (2) were case reports, reviews, letters or animal studies or (3) did not report survival outcomes.

Study quality assessment {#s2c}
------------------------

Two reviewers independently assessed the quality of included studies using the standard Newcastle-Ottawa Scale (NOS) from 0 to 9. NOS scores of 9--7 were defined as high quality, 6--4 as intermediate quality and 3--1 as low quality.

Data extraction {#s2d}
---------------

Two researchers (YHR and FJZ) independently screened all titles and abstracts identified in the initial search. Articles remaining after this screen were read in full and assessed for eligibility. The following types of data were extracted: (1) name of first author, publication year, country, type of cancer and number of patients; (2) patient's age, gender, follow-up time, type of LKB1 assay, intracellular location where LKB1 staining was examined, LKB1 cut-off value for classifying expression as high or low, survival data (OS, DFS, RFS), statistical method used to analyse survival data; (3) tumour differentiation, tumour size, lymph node metastasis and tumour stage. All data were cross-checked by two researchers, and disagreements were resolved by a third reviewer (XMY). If study information was incomplete or unclear, we contacted the corresponding author in an attempt to collect accurate information.

Statistical analysis {#s2e}
--------------------

Correlation between LKB1 expression and OS of patients with solid tumours was evaluated in terms of HR and 95% CI. If a study showed Kaplan-Meier survival curves but not HRs with 95% CI, data were extracted from survival curves using Engauge Digitizer 4.1 and the Tierney's table. Correlation between LKB1 expression and clinicopathological characteristics of patients with solid tumours was evaluated in terms of OR and 95% CI.

HRs and ORs were meta-analysed using the random-effects model in R software. P values were two-sided and values \<0.05 were considered to be statistically significant.

*I*² was used to assess statistical heterogeneity. If *I*² was \>50%, heterogeneity was considered to exist among all included studies, and we conducted a subgroup analysis to investigate its possible source. If *I*² was \<50%, heterogeneity among all included studies was regarded as insignificant, and data were directly pooled.

To assess the stability of our meta-analysis results, we conducted a sensitivity analysis to test the influences of individual studies on the pooled HR or p value for the remaining studies. Potential for publication bias was assessed by examining funnel plots, Begg's test and Egger's test of survival data.

Results {#s3}
=======

A total of 4858 potentially relevant studies were identified in literature searches, of which 3374 were excluded as duplicate publications. After screening titles and abstracts, 50 studies were read in full, leading to 25 that were included in the meta-analysis[@R12] ([figure 1](#F1){ref-type="fig"}). Data from all 25 studies were meta-analysed to examine the potential correlation of LKB1 expression with clinicopathological characteristics. Data from 24 studies were meta-analysed to examine the potential correlation between LKB1 expression and OS. Data from five studies were used to analyse the potential correlation between LKB1 expression and DFS. Four studies reported the association of LKB1 expression with RFS.

![Flow diagram of the eligible studies. CNKI, Chinese National Knowledge Infrastructure; LKB1, liver kinase B1.](bmjopen-2018-027185f01){#F1}

Description of studies {#s3a}
----------------------

The 25 studies in the systematic review involved 6012 patients from six countries: China, the USA, France, the UK, Canada and Egypt. Data on OS were reported in 24 studies, data on RFS in 5 studies and data on DFS in 4 studies. Patients covered a range of cancers, including cancers of the lung, breast, prostate or pancreas; gastric cancer; hepatocellular carcinoma; oesophagus squamous cancer; colorectal cancer; glioma and laryngeal squamous cell carcinoma. [Tables 1--2](#T1 T2){ref-type="table"} summarise the characteristics of the included studies. Online [supplementary table 1](#SP1){ref-type="supplementary-material"} lists clinicopathological characteristics and LKB1 expression. Eight studies had a NOS score of 8; 11 studies, 7; 6 studies, 6 and 3 studies, 5 (online [supplementary table 2](#SP2){ref-type="supplementary-material"} and online [supplementary table 3](#SP3){ref-type="supplementary-material"}).
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###### 

Main characteristics of included studies and Newcastle-Ottawa Scale (NOS) scores

  Study                                    Year   Country         Type of cancer                      No. of cases   Age (years), median (range)   Follow-up, mo.   NOS score   
  ---------------------------------------- ------ --------------- ----------------------------------- -------------- ----------------------------- ---------------- ----------- ---
  Ding XM[@R12]                            2005   China           Lung adenocarcinoma                 24             38                            60.5 (32--77)    80          7
  Tsai LH[@R13]                            2013   China           Lung adenocarcinoma                 44             71                            NR               140         7
  Jiang LL *et al* [@R14]                  2014   China           Non-small cell lung cancer          33             109                           58.2 (31--84)    71          7
  Calles A *et al* [@R15]                  2015   USA             Lung adenocarcinoma                 42             84                            63.5 (30--84)    60          7
  Shen Z *et al* [@R16]                    2002   China           Breast carcinoma                    38             83                            53.7 (32--77)    70          6
  Bouchekioua-Bouzaghou K *et al* [@R17]   2014   France          Breast cancer                       94             60                            56.87 (27--87)   162         7
  Bouchekioua-Bouzaghou K *et al* [@R17]   2014   France          Breast cancer                       102            52                            56.5 (27--87）   162         
  Chen IC *et al* [@R18]                   2016   China           Breast cancer                       161            408                           48               120         6
  Chen IC *et al* [@R18]                   2016   China           Breast cancer                       88             189                           54               120         
  Chen IC *et al* [@R18]                   2016   UK and Canada   Breast cancer                       494            494                           61.3             300         5
  Chen IC *et al* [@R18]                   2016   UK and Canada   Breast cancer                       488            487                           62.6             300         
  HamdyA.Azim *et al* [@R19]               2016   Egypt           Breast cancer                       12             20                            51.3 (25--82)    82.8        6
  HamdyA.Azim *et al* [@R19]               2016   Egypt           Breast cancer                       11             21                            51.3 (25--82)    82.8        
  Morton JP *et al* [@R20]                 2010   UK              Pancreatic cancer                   20             86                            NR               95          7
  Yang JY *et al* [@R21]                   2015   China           Pancreatic ductal adenocarcinoma    36             169                           NR               97          8
  Li DZ *et al* [@R23]                     2018   China           Pancreatic neuroendocrine tumour    38             33                            NR               190         8
  Yang XW *et al* [@R22]                   2012   China           Gastric cancer                      76             24                            65 (31--85)      38          7
  Huang Y *et al* [@R24]                   2014   China           Gastric carcinoma                   24             91                            61 (37--80)      75          6
  Ma LG *et al* [@R25]                     2016   China           Gastric cancer                      62             47                            57 (31--84)      99          8
  Sun JJ *et al* [@R36]                    2016   China           Gastric cancer                      107            48                            NR               70          6
  Yin M *et al* [@R26]                     2017   China           Gastric cancer                      78             32                            62 (23--79)      72          7
  Huang YH *et al* [@R27]                  2013   China           Hepatocellular carcinoma            31             39                            57 (43--72)      68          7
  Lee SW *et al* [@R28]                    2015   China           Hepatocellular carcinoma            13             27                            NR               101         7
  Wu CC *et al* [@R29]                     2018   China           Hepatocellular carcinoma            41             52                            NR               54          7
  Wang JH[@R30]                            2015   China           Intrahepatic cholangiocarcinoma     187            129                           NR               99          8
  Ma JJ                                    2014   China           Oesophagus squamous cancer          73             47                            NR               60          8
  He TY *et al* [@R32]                     2014   China           Colorectal cancer                   63             95                            NR               80.5        5
  Lu JL *et al* [@R33]                     2015   China           Prostate cancer                     78             31                            NR               60          7
  Huang JH *et al* [@R27]                  2017   China           Glioma                              92             88                            50.8 (10--86)    118         8
  He SS *et al* [@R35]                     2017   China           Laryngeal squamous cell carcinoma   128            80                            NR               212.2       8

LKB1, liver kinase B1; NR, no resources.

###### 

LKB1 expression levels and survival

  Study                                    Assay method      Staining location            Cut-off value                                                            Outcome   Analysis method           HR and 95% CI
  ---------------------------------------- ----------------- ---------------------------- ------------------------------------------------------------------------ --------- ------------------------- --------------------------
  Ding XM[@R12]                            IHC               Both nucleus and cytoplasm   Lower than in normal airway epithelium                                   OS        UA                        3.003 (1.524 to 5.865)
  Tsai LH *et al* [@R13]                   IHC               No specific description      Score ≤100                                                               OS        UA                        1.846 (1.147 to 2.952)
                                                                                                                                                                   MA        1.868 (1.160 to 3.007)    
                                                                                          RFS                                                                      UA        1.828 (1.247 to 3.122)    
                                                                                                                                                                   MA        1.791 (1.132 to 2.834)    
  Jiang LL *et al* [@R14]                  IHC               Cytoplasm                    Score 0--4                                                               OS        UA                        3.226 (1.856 to 5.586)
                                                                                                                                                                   MA        2.128 (1.136 to 4.000)    
  Calles A *et al* [@R15]                  IHC               Cytoplasm                    No staining                                                              OS        UA                        1.440 (0.910 to 2.270)
  ShenZ *et al* [@R16]                     WB                Total protein                Bands of the breast cancer tissue in which the quantities were \<0.5     OS        UA                        3.754 (1.583 to 8.932)
                                                                                          DFS                                                                      UA        2.529 (1.383 to 5.933)    
  Bouchekioua-Bouzaghou K *et al* [@R17]   IHC               Cytoplasm                    Staining intensity recorded as 0--1                                      OS        UA                        0.418 (0.211 to 0.828)
                                                                                                                                                                   MA        0.403 (0.199 to 0.820)    
                                                                                          DFS                                                                      UA        0.495 (0.249 to 0.809)    
                                                                                                                                                                   MA        0.549 (0.303 to 0.990)    
  Bouchekioua-Bouzaghou K *et al* [@R17]   IHC               Nucleus                      Staining intensity recorded as 0                                         OS        UA                        1.417 (0.722 to 2.734)
                                                                                          DFS                                                                      UA        1.278 (0.732 to 2.225)    
  Chen IC *et al* [@R18]                   IHC               No specific description      Score 0 or 1                                                             OS        UA                        1.200 (0.670 to 2.150)
                                                                                                                                                                   MA        0.766 (0.453 to 1.296)    
  Chen IC *et al* [@R18]                   IHC               No specific description      Score 0 or 1                                                             OS        UA                        0.980 (0.600 to 1.610)
                                                                                                                                                                   MA        1.054 (0.665 to 1.671)    
  Chen IC *et al* [@R18]                   Microarray data   No specific description      Lower than the median expression level                                   OS        UA                        1.600 (1.360 to 1.894)
                                                                                                                                                                   MA        0.937 (0.772 to 1.138)    
  Chen IC *et al* [@R18]                   Microarray data   No specific description      Lower than the median expression level                                   OS        UA                        1.090 (0.910 to 1.300)
                                                                                                                                                                   MA        1.024 (0.839 to 1.250)    
  HamdyA.Azim *et al* [@R19]               IHC               Cytoplasm                    Staining intensity recorded as 0                                         RFS       UA                        1.110 (0.160 to 7.490)
                                                                                                                                                                   MA        0.810 (0.220 to 3.030)    
  HamdyA.Azim *et al* [@R19]               IHC               Nucleus                      Staining intensity recorded as 0                                         RFS       UA                        5.220 (0.23 to 118.460)
                                                                                                                                                                   MA        0.360 (0.150 to 0.100)    
  Morton JP *et al* [@R20]                 IHC               Cytoplasm                    Histoscore ≤100                                                          OS        UA                        1.877 (1.020 to 3.448)
                                                                                                                                                                   MA        1.870 (1.090 to 3.220)    
  Yang JY *et al* [@R21]                   IHC               No specific description      Total score \<4                                                          OS        UA                        2.278 (1.495 to 3.472)
                                                                                                                                                                   MA        1.845 (1.189 to 2.856)    
  Li DZ *et al* [@R23]                     IHC               Cytoplasm                    Strong immunostaining in ≤50% of the cells and/or weak staining          OS        UA                        5.310 (0.200 to 142.482)
                                                                                          DFS                                                                      UA        2.190 (0.410 to 11.700)   
  Yang XW[@R22]                            IHC               Both nucleus and cytoplasm   Staining intensity in the neoplasm less than that in normal mucosa       OS        UA                        2.558 (1.554 to 4.233)
  Huang Y *et al* [@R24]                   IHC               Both nucleus and cytoplasm   Staining intensity recorded as 0--1                                      OS        UA                        2.514 (1.260 to 5.022)
  Ma LG *et al* [@R25]                     IHC               Both nucleus and cytoplasm   Scores ≤1                                                                OS        UA                        2.310 (1.250 to 4.270)
                                                                                                                                                                   MA        3.527 (1.491 to 10.630)   
  Sun JJ *et al* [@R36]                    IHC               Both nucleus and cytoplasm   Scores of 0 and 1+ indicate negative result                              OS        UA                        1.450 (0.540 to 3.900)
                                                                                                                                                                   MA        4.431 (1.363 to 14.407)   
  Yin M *et al* [@R26]                     IHC               Both nucleus and cytoplasm   Staining intensity recorded as 0--1                                      OS        UA                        1.070 (0.460 to 2.470）
  Huang YH *et al* [@R27]                  IHC               Cytoplasm                    Staining index score ≤3                                                  OS        UA                        3.155 (1.603 to 6.211)
                                                                                                                                                                   MA        2.179 (1.066 to 4.44)     
                                                                                          DFS                                                                      UA        2.737 (1.629 to 6.271)    
  Lee SW *et al* [@R28]                    IHC               Both nucleus and cytoplasm   H-score was lower than the median                                        OS        UA                        0.517 (0.284 to 0.931)
                                                                                                                                                                   MA        0.333 (0.193 to 0.564)    
  Wu CC *et al* [@R29]                     IHC               No specific description      Histoscore ≤150                                                          OS        UA                        3.130 (0.910 to 10.840)
                                                                                                                                                                   MA        4.260 (1.870 to 9.690)    
                                                                                          RFS                                                                      UA        2.020 (0.870 to 4.720)    
                                                                                                                                                                   MA        2.050 (1.110 to 3.810)    
  Wang JH[@R30]                            IHC               Cytoplasm                    Staining density lower than the median value                             OS        UA                        1.857 (1.438 to 2.386)
                                                                                                                                                                   MA        1.824 (1.404 to 2.377)    
  Ma JJ *et al* [@R25]                     IHC               Both nucleus and cytoplasm   Score 0--4                                                               OS        UA                        0.570 (0.330 to 0.980)
  He TY *et al* [@R32]                     IHC               No specific description      Score ≤100                                                               OS        UA                        2.364 (1.466 to 3.812)
                                                                                                                                                                   MA        3.146 (1.876 to 5.276)    
                                                                                          RFS                                                                      UA        2.522 (1.701 to 4.445)    
                                                                                                                                                                   MA        3.093 (1.843 to 5.191)    
  Lu JL *et al* [@R33]                     IHC               No specific description      Staining of fewer than 20% of the tissue cells or no staining            OS        UA                        6.310 (0.420 to 94.730)
                                                                                                                                                                   MA        3.981 (1.698 to 9.336)    
  Huang JH *et al* [@R34]                  IHC               No specific description      Percentage of positive cells ≤35% and/or staining intensity score 0--1   OS        UA                        3.350 (1.490 to 7.510)
                                                                                                                                                                   MA        3.022 (1.002 to 6.016)    
  He SS *et al* [@R35]                     IHC               Nucleus                      Score ≤4                                                                 OS        UA                        1.170 (0.720 to 1.900)
                                                                                                                                                                   MA        1.628 (1.060 to 2.500)    

DFS, disease-free survival; IHC, immunohistochemistry; LKB1, liver kinase B1; MA, multivariate analysis; OS, overall survival; RFS, relapse-free survival; UA, univariate analysis; WB, western blot.

Of the 25 studies, 16 reported HRs from multivariate analysis, which we used directly. For the nine remaining studies, we estimated HRs for OS, DFS and RFS from survival curves and Tierney's table.

Association between LKB1 expression and OS {#s3b}
------------------------------------------

Given heterogeneity among the studies (*I*²=74.0%, p\<0.001), a random-effects model was used to meta-analyse the data. The pooled HR describing OS for patients with low LKB1 expression relative to OS for patients with high expression is shown in [figure 2](#F2){ref-type="fig"}. Decreased LKB1 expression was significantly associated with OS: low expression was associated with significantly higher risk of poor survival (HR=1.63, 95% CI 1.35 to 1.97, p\<0.01).

![Forest plot of the association between decrease liver kinase B1 expression and overall survival.](bmjopen-2018-027185f02){#F2}

To assess the predictive role of decreased LKB1, subgroup analysis was performed after stratifying the results based on multivariate analysis, type of LKB1 assay, country, cancer type and intracellular location of LKB1 staining that was examined. Subgroup analysis based on multivariate analysis showed that decreased LKB1 expression was related to poor OS in [table 3](#T3){ref-type="table"} (HR=1.61, 95% CI 1.26 to 2.06, p\<0.001 with significant heterogeneity). This relationship was observed for the following cancer types: lung cancer (HR=2.07, 95% CI 1.60 to 2.69, p\<0.01, *I*²=0%), pancreatic cancer (HR=2.16, 95% CI 1.53 to 3.05, p\<0.001, *I*²=0%), gastric cancer (HR=2.11, 95% CI 1.60 to 3.01, p\<0.01, *I*²=0%) and breast cancer (HR=1.26, 95% CI 1.15 to 1.37, p\<0.01). However, this relationship was not observed in the case of hepatocellular carcinoma (HR=1.27, 95% CI 0.84 to 1.94, p=0.26 with significant heterogeneity).

###### 

Subgroup analyses of the association between LKB1 expression and OS after stratification by statistical analysis method, LKB1 assay method, region, cancer type and intracellular staining location

  Stratification criterion   Value                        HR (95% CI)           P value   Heterogeneity   
  -------------------------- ---------------------------- --------------------- --------- --------------- ---------
  Analysis method            Univariate                   1.63 (1.35 to 1.97)   \<0.001   74%             \<0.001
  Multivariate               1.61 (1.26 to 2.06)          \<0.001               81%       \<0.001         
  Assay method               IHC                          1.58 (1.33 to 1.88)   \<0.001   76%             \<0.001
  Region                     Asian                        1.70 (1.42 to 2.05)   \<0.001   77%             \<0.001
  Not Asian                  1.15 (0.63 to 2.08)          0.65                  75%       0.007           
  Cancer type                Lung                         2.07 (1.60 to 2.69)   \<0.001   53%             0.09
  Breast                     1.26 (1.15 to 1.37)          \<0.001               79%       \<0.001         
  Gastric                    2.11 (1.60 to 3.01)          \<0.001               0%        0.41            
  Pancreatic                 2.16 (1.53 to 3.05)          \<0.001               0%        0.76            
  Hepatocellular carcinoma   1.27 (0.84 to 1.94)          0.26                  89%       \<0.001         
  Others                     1.63 (1.35 to 1.96)          \<0.001               79%       \<0.001         
  Staining position          Both nucleus and cytoplasm   1.50 (1.31 to 1.17)   \<0.001   80%             \<0.001
  Cytoplasm                  1.78 (1.49 to 2.13)          \<0.001               77%       \<0.001         
  Nucleus                    1.25 (0.85 to 1.85)          0.26                  0%        0.65            
  Others                     1.36 (1.25 to 1.47)          \<0.001               75%       \<0.001         
  NOS scores                 High quality                 1.53 (1.19 to 1.96)   \<0.001   77%             \<0.001
  Intermediate quality       1.79 (1.36 to 1.92)          \<0.001               75%       \<0.001         

IHC, immunohistochemistry; LKB1, liver kinase B1; NOS, Newcastle-Ottawa Scale; OS, overall survival; RFS, relapse-free survival.

Among Asian patients, decreased LKB1 expression was associated with significantly shorter OS (HR=1.70, 95% CI 1.42 to 2.05, p\<0.01); this relationship was not observed among non-Asian patients (HR=1.15, 95% CI 0.63 to 2.08, p=0.65) [(table 3](#T3){ref-type="table"}).

Pooled HR for the subgroup of patients tested by anti-LKB1 immunohistochemistry was 1.58 (95% CI 1.33 to 1.88, p\<0.01). Low LKB1 expression based on cytoplasmic staining predicted significant adverse prognosis (HR=1.78, 95% CI 1.49 to 2.13, p\<0.01). This relationship was not observed when the judgement of low LKB1 expression was based on nuclear staining (HR=1.25, 95% CI 0.85 to 1.85, p=0.26, *I*²=0%) ([table 3](#T3){ref-type="table"}).

Details of the subgroup analysis are listed in [table 3](#T3){ref-type="table"}. The results of the sensitivity analysis showed that the exclusion of each single study did not alter the results significantly ([figure 3](#F3){ref-type="fig"}). These results suggest that our meta-analysis gave credible results.

![Sensitivity analysis of overall survival in the meta-analysis.](bmjopen-2018-027185f03){#F3}

Association of LKB1 expression with DFS and RFS {#s3c}
-----------------------------------------------

Studies showed significant heterogeneity, so data were meta-analysed using a random-effects model. Low LKB1 expression did not show a significant association with RFS based on univariate analysis (HR=1.44, 95% CI 0.65 to 3.17, p=0.37) or multivariate analysis (HR=1.02, 95% CI 0.42 to 2.47, p=0.97). Similarly, no significant correlation was observed between LKB1 expression and DFS based on univariate analysis and random-effects meta-analysis (HR=1.49, 95% CI 0.73 to 3.01, p=0.27) ([table 4](#T4){ref-type="table"}).

###### 

Meta-analysis results of decreased LKB1 expression and patient's prognosis

  Prognosis               Analysis method       HR (95% CI)           P value   Heterogeneity   
  ----------------------- --------------------- --------------------- --------- --------------- -----------
  OS                      Univariate analysis   1.63 (1.35 to 1.97)   \<0.01    74.0%           \<0.001
  Multivariate analysis   1.61 (1.26 to 2.06)   \<0.001               81.0%     *\<*0.001       
  RFS                     Univariate analysis   1.44 (0.65 to 3.17)   0.37      85%             *\<*0.001
  Multivariate analysis   1.02 (0.42 to 2.47)   0.97                  95%       *\<*0.001       
  DFS                     Univariate analysis   1.49 (0.73 to 3.01)   0.27      78%             0.001

DFS, disease-free survival; LKB1, liver kinase B1; OS, overall survival; RFS, relapse-free survival.

Association between LKB1 expression and clinicopathological characteristics {#s3d}
---------------------------------------------------------------------------

Meta-analysis of the relationship between LKB1 expression and clinicopathological characteristics ([table 5](#T5){ref-type="table"}) failed to show a significant association of decreased LKB1 expression with age (OR=0.78, 95% CI 0.57 to 1.05, p=0.10) or sex (OR=0.97, 95% CI 0.78 to 1.19, p=0.76). In contrast, low LKB1 expression was significantly related to worse differentiation (OR=1.17, 95% CI 1.14 to 2.55, p\<0.01), deeper invasion (OR=1.68, 95% CI 1.24 to 2.27, p\<0.01), earlier lymph node metastasis (OR=1.43, 95% CI 1.26 to 1.62, p\<0.01) and more advanced clinical stage (OR=1.80, 95% CI 1.56 to 2.07, p\<0.01).

###### 

Meta-analysis of the association of decreased LKB1 expression with clinicopathological characteristics

                                        OR (95% CI)           P value   Heterogeneity         
  ------------------------------------- --------------------- --------- --------------- ----- ---------
  Age (≥60, \<60 years)                 0.78 (0.57 to 1.05)   0.10      4.04            0%    0.78
  Sex (male, female)                    0.97 (0.78 to 1.19)   0.76      9.06            0%    0.77
  Tumour differentiation (poor, well)   1.71 (1.14 to 2.55)   \<0.01    59.5            75%   \<0.001
  Tumour size (T3--T4, T1--T2)          1.68 (1.24 to 2.27)   \<0.01    43.34           61%   \<0.001
  Lymph node metastasis (yes, no)       1.43 (1.26 to 1.62)   \<0.01    58.41           74%   \<0.001
  TNM stage (Ⅲ--Ⅳ, Ⅰ--Ⅱ)                1.80 (1.56 to 2.07)   \<0.01    88.8            81%   \<0.001

LKB1, liver kinase B1; TNM, tumour, node, metastases.

Results are shown as individual and pooled OR with 95% CIs.

Publication bias {#s3e}
----------------

Funnel plots of OS appeared asymmetric ([figure 4](#F4){ref-type="fig"}), suggesting the possibility of publication bias among the included studies. However, findings with Begg's test (p=0.5402) and Egger's test (p=0.2414) implied no publication bias.

![Funnel plot for the potential publication bias.](bmjopen-2018-027185f04){#F4}

Discussion {#s4}
==========

This meta-analysis suggests that among patients with many kinds of solid tumours, low LKB1 expression is associated with worse OS, whereas LKB1 expression does not appear to significantly influence DFS or RFS. This suggests that low LKB1 expression may be a predictor of unfavourable prognosis. In fact, the available evidence suggests an association of low LKB1 expression with worse tumour differentiation, deeper invasion, more advanced clinical stages and earlier metastasis to lymph nodes and other organs. These findings are consistent with previous conclusions,[@R11] and they were confirmed in our data set using sensitivity analysis.

Some potentially interesting findings emerged from subgroup analyses conducted after stratifying the data according to various criteria. Our meta-analysis linked low LKB1 expression with poor prognosis in Asians but not in non-Asians, which may reflect genetic and environmental differences. While low LKB1 expression was associated with worse prognosis in patients with certain types of cancer (lung, gastric, pancreatic, breast), this was not the case in patients with hepatocellular carcinoma. This difference may relate to different comorbidities associated with the types of cancer. Lung cancer, stomach cancer, breast cancer and pancreatic cancer have high incidence rates around the world, and more studies have been done. The association between low expression of LKB1 and poor prognosis was observed when low expression was based on cytoplasmic staining, but not when it was based on nuclear staining. The reason may be that the regulation of mTORC1 by LKB1 and AMPK occurs on the exterior of RAB7/LAMP1-positive lysosomal membranes.[@R37] In this regulation, LKB1 phosphorylates and activates cell energy-sensing AMPK, which in turn negatively affects TORC1, which is important for controlling energy metabolism, cell survival and cell growth under conditions of metabolic stress, such as nutrient deficiency. Further studies are needed to elucidate the mechanism of action of LKB1.

Our meta-analysis suggests that at least in many types of solid tumours, LKB1 acts as a tumour suppressor. This is consistent with several studies in the literature. For example, a decrease in LKB1 expression as a result of HBx-mediated p53 inactivation may be responsible for colony formation and invasiveness in hepatocellular carcinoma.[@R29] LKB1 deficiency in some tumours may be associated with upregulation of glutamate dehydrogenase 1, which activates CamKK2 and its downstream effector AMPK to increase metastatic potential.[@R38] LKB1 loss may drive ovarian serous tumourigenesis by disrupting apical-basal polarity in the presence of mutated p53 in fallopian tube cells.[@R39] On the one hand, several studies have suggested an oncogenic role for LKB1 and AMPK under certain conditions,[@R40] such as when class III phosphatidylinositol-3-OH kinase is inactivated.[@R41] Further work is needed to clarify under what conditions LKB1 acts as a tumourigenic or tumour-suppressing molecule.

The results of our meta-analysis should be interpreted with caution given several limitations. First, we had to assess OS, DFS and/or RFS from Kaplan-Meier survival curves in several studies, such that HRs and 95% CIs were estimated indirectly. Second, studies showed substantial heterogeneity for outcomes, although we did attempt to minimise the effects of such heterogeneity by using a random-effects meta-analysis model, performing subgroup analyses and checking results through sensitivity analysis. Third, there is no consensus on LKB1 cut-off values for defining expression as low or high, which may influence conclusions about correlations and their clinical significance. Fourth, the funnel plots suggest the potential for publication bias. This may reflect the generally observed bias towards publication of positive findings. Fifth, our meta-analysis did not account for numerous other factors that may also affect prognosis, such as comorbidities and treatment history. In most cases, this information was not reported in the included studies.

Our results justify the design of rigorous in vitro and animal studies designed to explore how LKB1 influences the prognosis of various types of solid cancers. Ultimately, this work should be extended through human studies, preferentially randomised controlled trials.

Conclusions {#s5}
===========

The available evidence links low LKB1 expression with poor prognosis in patients with various types of solid tumours. This suggests that LKB1 may be a biomarker for various cancers. These findings should be verified and extended in human studies, and the mechanisms underlying the association of LKB1 expression and prognosis should be explored.
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